Discover. Predict. Detect.
OneCare combines three complementary technologies: hypothesis-free biomarker discovery, AI-powered molecular signature analysis, and graphene biosensors to transform a single blood draw into an objective psychiatric diagnostic signal.
Discover
Instead of searching for one predefined biomarker, we use billions of aptamers to discover disease-specific biological signatures directly from blood.
Most biomarker tests look for one or a handful of proteins. Our Aptamarker platform uses aptamers, short, lab-engineered molecules that bind target molecules with antibody-like specificity, to simultaneously capture thousands of circulating biomarkers across the full multiomic landscape, not just proteins.
This means we screen broadly across the multiome, proteins, metabolites, and other circulating molecules, capturing all blood molecules without discrimination, including non-canonical and previously overlooked forms. That "wide net" approach opens the window for discovery, letting the full molecular landscape reveal which combinations of signals are actually predictive of psychiatric illness, rather than betting on one candidate biomarker at a time.
Aptamer binding to molecule
Predict (AI Prediction Engine)
AI learns complex molecular patterns that predict diagnosis, treatment response, and disease progression.
Psychiatric illness rarely shows up as one abnormal value; it's encoded in subtle, multi-omic patterns. Our machine learning models are trained to detect these patterns across hundreds of biomarker features per patient, cross-referencing them against validated disease signatures.
This is what turns raw molecular data into a reproducible, clinically actionable score. AI isn't an add-on to our platform; it's the layer that makes the wide-net biomarker approach clinically useful at all.
Detect
Once the right molecular signatures have been identified, our graphene biosensors enable their rapid and direct detection from a blood sample.
Our graphene field-effect transistor (gFET) platform detects target biomarkers in real time without labeling, amplification, or complex centralized laboratory workflows. By converting molecular interactions directly into electrical signals, it provides a fast, sensitive, and scalable approach to molecular diagnostics.
With exceptional sensitivity and multiplexing capabilities, our graphene sensing platform is designed to bring precision diagnostics closer to the point of care, enabling rapid, objective molecular testing in routine clinical practice.
From first episode to a clear treatment path
Our point-of-care device turns a single blood draw into a treatment recommendation, often within the hour.
First Episode
A patient experiences their first episode of psychosis and is brought in for evaluation.
Point-of-Care Test
The patient takes a simple blood test using our point-of-care device, right at the clinic.
Treatment, Within the Hour
Within the hour, the clinician receives a clear recommendation for the most effective treatment.
Publications
Peer-reviewed research and preprints from the OneCare team.